Amgen Inc. Stock price

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
270.9 USD +0.76% Intraday chart for Amgen Inc. -1.62% -5.94%
Sales 2024 * 33.01B Sales 2025 * 34.06B Capitalization 144B
Net income 2024 * 6.12B Net income 2025 * 7.57B EV / Sales 2024 * 5.78 x
Net Debt 2024 * 46.64B Net Debt 2025 * 41.16B EV / Sales 2025 * 5.44 x
P/E ratio 2024 *
23.5 x
P/E ratio 2025 *
18.2 x
Employees 26,700
Yield 2024 *
3.42%
Yield 2025 *
3.7%
Free-Float 99.63%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.76%
1 week-1.04%
Current month-1.07%
1 month-4.51%
3 months-1.65%
6 months+3.90%
Current year-5.94%
More quotes
1 week
268.17
Extreme 268.17
278.56
1 month
268.17
Extreme 268.17
292.24
Current year
268.17
Extreme 268.17
329.72
1 year
211.71
Extreme 211.71
329.72
3 years
198.64
Extreme 198.64
329.72
5 years
166.30
Extreme 166.3
329.72
10 years
108.20
Extreme 108.2
329.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 06-05-31
Director of Finance/CFO 65 19-10-22
Chief Tech/Sci/R&D Officer 53 -
Members of the board TitleAgeSince
Director/Board Member 67 17-02-02
Director/Board Member 68 16-10-13
Director/Board Member 75 14-10-16
More insiders
Date Price Change Volume
24-03-18 270.9 +0.76% 3,608,491
24-03-15 268.9 -0.98% 8,795,786
24-03-14 271.5 -1.61% 2,370,492
24-03-13 276 -0.20% 1,641,024
24-03-12 276.5 +0.43% 1,738,941

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.6% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
270.9 USD
Average target price
304.1 USD
Spread / Average Target
+12.27%
Consensus
  1. Stock
  2. Equities
  3. Stock Amgen Inc. - Nasdaq